Jasper Therapeutics, Inc. (JSPR) NASDAQ
0.48
-0.051(-9.58%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.48
-0.051(-9.58%)
Currency In USD
| Previous Close | 0.53 |
| Open | 0.52 |
| Day High | 0.59 |
| Day Low | 0.46 |
| 52-Week High | 7.19 |
| 52-Week Low | 0.43 |
| Volume | 864,848 |
| Average Volume | 508,646 |
| Market Cap | 7.82M |
| PE | -0.19 |
| EPS | -2.58 |
| Moving Average 50 Days | 0.89 |
| Moving Average 200 Days | 1.67 |
| Change | -0.05 |
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
GlobeNewswire Inc.
Feb 24, 2026 9:30 PM GMT
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
GlobeNewswire Inc.
Jan 07, 2026 9:30 PM GMT
Thomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study in CSU and CIndU REDWOOD CITY, Calif., Jan. 07, 2